Clinical Trial

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Study acronym: RAD301
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
Protocol Amendment History 4 changes
notable Primary completion pushed: 2026-05 -> 2026-08 2026-07-19
minor Completion pushed: 2026-05 -> 2026-08 2026-07-19
notable Primary completion pushed: 2026-03 -> 2026-05 2026-05-06
minor Completion pushed: 2026-03 -> 2026-05 2026-05-06
Trial Details
NCT Number NCT05799274
Lead Sponsor Radiopharm Theranostics, Ltd
Conditions Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Enrollment 9 participants
Start Date 2023-11-09
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-17